Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results released for quarter ended March 31, 2026.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results released for quarter ended March 31, 2026
- Full results and management commentary furnished in Exhibit 99.1
- Investor focus: quarterly performance, liquidity, and guidance disclosed in the attached release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.